Clinical Trials Browser

Active not recruiting × Interventional × tucatinib × Clear all

NCT05132582 2026-03-16

HER2CLIMB-05

Phase 3 Active not recruiting

Breast Neoplasms

NCT05382364 2026-03-12

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Phase 1 Active not recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04721977 2026-01-09

MK-7119-001

Phase 2 Active not recruiting

66 enrolled 7 charts

Breast Neoplasms

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Phase 3 Active not recruiting

466 enrolled 17 charts

HER2-positive Breast Cancer

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

Phase 2 Active not recruiting

Metastatic Breast Cancer With a Isolated Brain Progression

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer